Physician profile
Chanda Kaur
NPI 1912584632
$1,323.82
in general payments reported to CMS, 2019-2025
20 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $405 · 2023: $164 · 2024: $109 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $193.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.05 | 2022-2025 | |
| Amgen INC. | $178.69 | 2022-2023 | Repatha, Otezla |
| Novo Nordisk INC | $123.42 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.84 | 2022-2025 | Jardiance, Synjardy, Glyxambi |
| Boston Scientific Corporation | $86.12 | 2024-2025 | Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $81.38 | 2021-2022 | |
| Madrigal Pharmaceuticals | $73.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $69.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $39.91 | 2021-2022 | |
| Lilly USA, LLC | $35.49 | 2022-2025 | Mounjaro |
| Avvisto Therapeutics, LLC | $28.19 | 2024 | Cycloset |
| Astrazeneca Pharmaceuticals LP | $27.29 | 2021 | |
| Abbvie INC. | $22.78 | 2021 | |
| Corcept Therapeutics | $19.92 | 2025 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $19.14 | 2021 | |
| Seqirus USA INC | $15.00 | 2022 | |
| Medtronic, INC. | $13.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.69 | 2022 | |
| Genentech USA, INC. | $2.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanda Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.